The FDA, too, has cautioned about the potential danger of the compounds, and leading obesity medicine groups starkly warn patients against their use
The Novel GIP, GLP-1 and Glucagon Receptor Agonist Retatrutide for the Treatment of Type 2 Diabetes: A Short Review on Potential Mechanisms and Clinical Evidence
Consider these evidence-based dietary strategies: Eat small, frequent, low-fat meals that are easier to digest Limit sugar alcohols (sorbitol, mannitol, xylitol) found in sugar-free products, which have known laxative effects Gradually increase soluble fiber through foods like oatmeal and psyllium supplements, which can help bulk stools Avoid excessive insoluble fiber from raw vegetables and whole grains during acute episodes Stay adequately hydrated with water and electrolyte-containing beverages to prevent dehydration Avoid spicy, greasy, or very high-fiber foods during episodes of diarrhea Medication dosing may require adjustment
329 Gupta, T
Although the pilot study was smaller, its results point in a similar direction, suggesting that GLP-1 therapies may affect biological aging pathways
Research-grade GLP-1 and GIP dual-agonist peptide commonly researched for weight management, appetite regulation, metabolic signalling, and glucose-response pathways
